Information Provided By: 
Fly News Breaks for August 9, 2016
ICUI
Aug 9, 2016 | 08:39 EDT
Roth Capital analyst Chris Lewis says ICU Medical delivered a Q2 beat and raised its 2016 outlook as Direct sales momentum and OEM/Hospira growth continued. Although the company expects an even steeper decline in Hospira over the second half of 2016, the analyst believes ICU Medical is well-positioned to sustain revenue growth on Direct strength and non-Hospira OEM channels, with margin expansion opportunities materializing in 2017. Lewis reiterates a Buy rating on the stock and raised his price target on the shares to $132 from $130.
News For ICUI From the Last 2 Days
There are no results for your query ICUI
